Melissa Badamo

DocwireNews

Mitapivat is a safe and effective treatment for patients with sickle cell disease (SCD), according to results from the phase II, double-blind portion of the RISE UP trial published in The Lancet Haematology.
The researchers evaluated the efficacy and safety of mitapivat, a first-in-class, oral, allosteric pyruvate kinase activator. Seventy-nine patients aged 16 years and older from 32 clinical sites across 13 countries were randomly assigned 1:1:1 to receive mitapivat at 50 mg (n=26), mitapivat at 100 mg (n=26), or placebo (n=27) twice daily. Patients had baseline hemoglobin levels of 5.5 to 10.5 g/dL and two to ten sickle cell pain crises within 12 months.
The primary efficacy endpoint was hemoglobin response (defined as a ≥1.0 g/dL increase from baseline in average hemoglobin concentration from week 10 through week 12). The primary safety endpoints were type and severity of adverse events (AEs) and the relationship between AEs and mitapivat.
Both treatment groups showed a statistically significant hemoglobin response rate compared with placebo, the authors noted. Specifically, 12 of 26 (46%) patients in the 50-mg group, 13 of 26 (50%) patients in the 100 mg group, and 1 of 27 (4%) patients in the placebo group achieved a statistically significant hemoglobin response rate (2-sided P=.0003 and P=.0001, respectively).
As for safety, 2 of 26 (8%) patients in the 50-mg group, 4 of 26 (15%) patients in the 100-mg group, and 3 of 27 (11%) patients in the placebo group reported AEs. The rates of grade 3 or higher AEs were 12% for the 50-mg group, 19% for the 100-mg group, and 7% for the placebo group.
The most common grade 3 or higher AEs were infections and infestations. This included one patient with meningitis and one with pelvic inflammatory disease in the 50-mg group; one patient each with malaria, pneumonia, and tonsillitis in the 100-mg group; and one patient with an infected skin ulcer in the placebo group. There were no serious AEs, grade 3 or higher AEs, or deaths that were considered treatment related.
“Mitapivat, through its dual effect of increasing ATP and decreasing 2,3-diphosphoglycerate, could provide clinical benefit to patients with sickle cell disease,” the researchers concluded. “These results support continued evaluation of mitapivat in the phase 3 portion of the study.”
Reference
Idowu M, Otieno L, Dumitriu B, et al. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial. Lancet Haematol. 2025;12(1):e35-e44. doi:10.1016/S2352-3026(24)00319-3

Shubham Pant, MD

Zanidatamab for Biliary Tract Cancer: The HERIZON Trial

Bile Duct Cancer

Laura Litwin

Sublobar Resection Versus Lobectomy for Early-Stage NSCLC: Systematic Review Compares Outcomes

Non-Small Cell Lung Cancer

Emily Menendez

Sotorasib Plus Panitumumab Approved by FDA for KRAS G12C-Mutated mCRC

Colorectal Cancer

Latest News

RISE UP Study Highlights Efficacy, Safety of Mitapivat in SCD

Sickle Cell Disease

Patients receiving mitapivat for SCD showed a statistically significant hemoglobin response rate compared with placebo.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe